The Centre has permitted the export of around 50 million doses of Covid-19 vaccine Covovax produced by Serum Institute of India (SII) as part of a tie-up with US-based vaccine maker Novavax Inc, according to people familiar with the developments.
Covovax has not been approved yet for emergency use in India. The government approval for the export of Covovax will help avoid wastage of nearly 10 million stockpiled Covovax doses which are due to expire in December. The vaccines were produced as part of SII’s agreement with Novavax Inc. for the development and commercialisation of NVX-CoV2373.
SII chief executive officer Adar Poonawalla earlier told HT in an interview that his company intended to keep Covovax and Sputnik Light, the first component of the Russian coronavirus vaccine Sputnik V, for exports.
“That is my sort of thinking and discussion with the government; and we are sort of aligned on that because Covishield is churning out enough volumes for the country… We do not need to increase the volumes; in fact anything more we make, we hope to export…,” Poonawalla said in an interview last month.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.